Fernández GS, Díaz GD, Díaz TM

Language: Spanish
References: 15
Page: 27-38
PDF size: 471.54 Kb.

ABSTRACT

Introduction: lung cancer is one of the leading causes of death in Cuba. The histological variant of non-small cells are the most frequent malignant tumors. More than half of the cases diagnosed are in advanced stages where the oncological theraphy is fundamentally based on polychemotheraphy. Objectives: to evaluate the clinical and imaging evolution of patients with stage III B non-small cell lung cancer treated with polychemoteraphy. Methods: an analytical observational study was conducted to evaluate the therapeutic response in 73 patients with stage III B non-small cell lung cancer treated with polychemotheraphy at the Pulmonary “Benefico Juridico” Hospital in the period from January 2015 to December 2017. The universe was the totality of patients diagnosed with non-small cell lung cancer. Functional variables, clinical manifestations and objective antitumor response were compared. Results: predominantly male patients (67,75%) and over 60 years old. Oncological treatment with polychemotheraphy significantly reduced weight loss and chest pain. There was a progressive worsening of functional status after treatment. Although the majority of patients showed some objective antitumor response, the remaining 43,8 % were in progression of the disease. Conclusions: the treatment with polychemotherapy reduced some of the symptoms, but it was not related to an improvement in the functional status. More than half of the patients were stable or with an objective antitumor response.

REFERENCES

1. National Comprehensive Cancer Network (NCCN). Non small cell lung cancer guidelines.[Internet] 2017 [consultado 24 Apr 2019]; 7(10): [50p] Disponible en: https://www.nccn.org/professionals/physician gls/f guidelines.asp

2. Fletcher CM, Elmes PC, Wood CH. The significance of respiratory symptoms and the diagnosis of chromic bronchitis in a working population. B.M.J 1978; 2: 241-243. [consultado 24 Apr 2019]. Disponible en: https://www.ncbi.nlm.nih.gov>pub

3. Rizvi NA, Hellmann MD, Brahmer J, Juergens RA, Borghaei H, Gettinger S, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first line treatment of advanced non small cell lung cancer. J Clin Oncol [Internet] 2016 [consultado 24 Apr 2019]; 34(8): [25p] Disponible en: https://www.ascopubs.org>doi>abs

4. Zubrod CG, Lopringi Cl y cols. Prospective evaluacion of prognostic variables from patients completed questionnaires. Performance Status Series. J Clin Oncol [Internet] 2014 [consultado 14 Apr 2019] 5(12): [60p] Disponible en: https://sciencedirect.com>pii>pdf

5. .Nishino M, et al. New response evaluation criteria in solid tumor (RECIST) guidelaines for advanced non small cell lung cancer: comparision with original recist and impact on assesment of tumor response to targeted therapy. Am J. Roentgenology [Internet] 2016 [consultado 24 Apr 2019];195 (3): [aproximadamente 40p] Disponible en: https://www.ncbi.nlm.nih.gov>m

6. Alonso Moraleja R, Sayas Catalán J, García Luján R, Coronado Poggio M, Monsó Molas E, López Encuentra A. Utilidad de la tomografía por emisión de positrones en la detección de metástasis ocultas extratorácicas en el carcinoma broncogénico no células pequeñas. Arch Bronconeumol [Internet] 2015 [consultado 2 March 2019]; 6(15): [aproximadamente 50p] Disponible en: https://www.medigraphic.com>new

7. Lima Guerra A, Gassiot Nuño C, Ramos Quevedo A, Rodríguez Vázquez JC, Cabanes Varona L. Conducta diagnóstica y pronóstico en pacientes con carcinoma pulmonar de células no pequeñas en estadios quirúrgicos. Rev cubana med. [Internet] 2012 [consultado 2 March 2019]; 51(1): [60p] Disponible en: https://www.ncbi.nlm.nih.gov

8. Orellana Meneses GA, Carpio Muñoz EL, Otero Echemendía Y, Domínguez Nieto J, Lorenzo Rubio JL. Características clínicas de pacientes con cáncer primario de pulmón en la provincia Sancti Spíritus. Cuba. Gaceta Médica Espirituana [Internet] 2016 [consultado 14 Apr 2019]; 13(3): [40p] Disponible en: https://www.ecured.cu>Gaceta_Médica

9. Díaz Garrido D, León Valdivies YJ, Fernández García S, Díaz Toledo M, Sánchez de la Osa R, Osés Herrera L. Respuesta al tratamiento oncoespecífico en carcinomas no microcíticos etapa IIIA no quirúrgica. Acta Médica Grupo Ángeles [Internet] 2017 [consultado 25 Feb 2019]; 15(1): [40p] Disponible en: https://www.scielo.sld.cu>scielo

10. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiology and Prevention Biomarkers. 2016; 25:16-27

11. Rodríguez Panadero F, López-Encuentra A. Tumores broncopulmonares. En: Farreras Valentí P, Rozman C, editores. Farreras-Rozman. Medicina Interna. (16. ed.) España: Elsevier; 2010.

12. Green S, Dawe DE, Banerji SJ. Immune signatures of non-small cell lung cancer. J Thorac Oncol. [Internet] 2017 [consultado 2 March 2019]; 9(12) : [65p] Disponible en: https://www.ncbi.nlm.nih.gov>pub

13. Montero C, Rosales M, Otero I, Blanco M, Rodríguez G, Peterga S, y colaboradores. Cáncer de pulmón en el área sanitaria de la Coruña: incidencia, abordaje clínico y supervivencia. Arch Bronconeumol. [Internet] 2018 [consultado 16 Feb 2019]; 6(39): 209-16 Disponible en: https://www.archbronconeumol.org

14. Gullón JA, Fernández R, Rubinos G, Medina A, Suárez I, González IJ. Carcinoma broncogénico no microcítico en estadios avanzados: influencia pronóstica de la pérdida de peso e implicaciones clínicas. Arch Bronconeumol.[Publicación periódica en línea] 2001 [consultado 16 Feb 2019].; 10(37): [80p] Disponible en: https://www.elsevier.es

15. Sánchez de la Rosa R, Ruiz J, Guillen F. Evaluación del tratamiento con paclitaxel del cáncer de pulmón no microcítico. Med Clin Barc. [Internet] 2001 [consultado 2 March 2019]; 10 (11): [100p] Disponible en: https://www.academia.edu